Navigation Links
A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Date:11/6/2007

REHOVOT, Israel, Nov. 6 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that the primary end point and safety evaluation in the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients was successfully completed. This event marks a major milestone in the development program of the compound MTR106 (tablet formulation of MTR104). MTR104 is a low molecular weight S-Alkylisothiouronium derivative.

This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR106 in female patients suffering from migraine without aura. The study population consisted of forty (40) female patients ranging from 22-57 years of age. The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of 2.8 +/- 1.3 attacks per month. The subjects were randomized in a ratio of 4:1: treatment to placebo respectively, constituting 4 groups of 10 patients each. Treatment arms of MTR106 or placebo were administered at escalating doses of 25, 50, 75 and 100 mg.

MTR106 was found to be safe and well tolerated. No serious adverse events occurred in the 4 studied doses and no symptoms related to chest pain or changes in heart rate or blood pressure were observed. The study results demonstrated that at 2 hours and at the 3rd and 4th hours post-treatment more patients treated with MTR106 had pain relief compared to those treated with placebo.

About Meditor Pharmaceuticals:

Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the tr
'/>"/>

SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... 25, 2014 Garth Brooks Chicago tickets ... Allstate Arena in Rosemont. Garth Brooks was one of the ... his first single in 1989. Since "Much Too Young (To Feel ... shows from the Tulsa, Okl. native and in the years that ... him back on a stage and in the recording studio. Between ...
(Date:7/25/2014)... An alpha olefin is an olefin or ... or alpha position of the carbon chain, or between the ... alpha-olefins, namely, branched and linear (or normal). The alpha olefin ... of its applications such as polyethylene co-monomers and synthetic lubricants, ... and Europe have been lucrative markets for alpha olefins; however, ...
(Date:7/25/2014)... more quickly after Manchester research , Clinical judgement, ... on arrival, is effective in reducing unnecessary hospital ... The findings of a research group in Manchester, ... make a huge difference to a large number ... reason for emergency hospital admission. In Manchester, the ...
(Date:7/25/2014)... cancer screening test results among some patients is real ... et al, published July 25 in Cancer , ... positive or other results of computed tomography (CT) lung ... some in the medical community. , "Unsubstantiated claims ... put to rest and not continue to delay implementation ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2
... outbreaks reported from Vietnam and South Korea has put ... stocked and ready to deal with the situation, if ... Ministry has a stock of 2.5 million capsules of ... doses of influenza vaccines to be given to risk ...
... autoimmune disorder marked by early skin lesions and ... this thickening and hardening of connective tissue affects ... and the heart. In SSc patients, fibrosis frequently ... Researchers have yet to determine the underlying cause ...
... New York: A new study has shown a connection ... breast cancer after menopause//. While there is little doubt that ... seems to be convincing evidence that weight gain in adult ... disease. , ,Yet, not much was known about the ...
... A California based company has developed a pill called Excalia ... researchers working for this announced// the results ... the North American Association for the Study of Obesity.This organisation ... obesity. They claim that this preparation can effectively help ...
... Bharatiya Janta Party has been inspired from the most ... family planning programme for the Muslim community// based on ... and clerics for awareness campaign as well as the ... the way of family planning is ignorance and not ...
... prompt women to both scale back risky drinking and ... ,Prenatal alcohol exposure is a leading preventable cause ... States. This CDC study explored a strategy that could ... ,“A lot of people find this to be ...
Cached Medicine News:Health News:New Treatment Offers Hope for Systemic Sclerosis 2Health News:Madhya Pradesh Imbibes Family Planning Lessons from Pakistan 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 3
... ophthalmic solution is an anti-infective ... doctor may instruct you to ... eye infection caused by bacteria. ... are the 2 types of ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: